Danish drug giant Novo Nordisk
Operating profit was up 25% in local currency and up 15% even after being converted to kroner, thanks to a reduction in research and development expenses. Following in the footsteps of Pfizer
Novo Nordisk has done well competing with Sanofi-Aventis'
The compound has already been shown to work as well as Amylin Pharmaceuticals
Novo Nordisk also has a decently stocked pipeline with the potential for liraglutide to be used as a treatment for obesity and a pair of next-generation insulins that are set to move into phase 3 trials next year.
Unless a recession starts making people eat better, the diabetes drug market is likely to continue to expand. Novo Nordisk is situated perfectly to take advantage of that growth no matter what continent it comes on.
Novo Nordisk is a Motley Fool Global Gains recommendation.Our newsletter scours the globe to find you the best investing opportunities, wherever they may be. Take a free look for 30 days and see how Global Gains can add diversity to your portfolio.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer and Eli Lilly are Income Investor picks. Pfizer is an Inside Value recommendation and the Fool owns shares of it. The Fool's disclosure policyis an international rock star.